Julien Lefranc

Merck (Germany) — Germany

Chemistry · Physical Sciences

14h-index1.3kcitations58works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Coordination Chemistry and Organometallics(11), Asymmetric Synthesis and Catalysis(10), DNA Repair Mechanisms(10), Crystallization and Solubility Studies(8), X-ray Diffraction in Crystallography(8)

Publications58 total

Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1
Journal of Medicinal Chemistry·2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy
Nucleic Acids Research·2025Open Access
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor
Journal of Medicinal Chemistry·2025· 2 cited
Intramolecular Lithiation‐Borylation for the Stereoselective Synthesis of Cyclopentyl and Cyclobutyl Bis‐Boronic Esters
Angewandte Chemie·2025· 1 citedOpen Access
Intramolecular Lithiation‐Borylation for the Stereoselective Synthesis of Cyclopentyl and Cyclobutyl Bis‐Boronic Esters
Angewandte Chemie International Edition·2025· 3 citedOpen Access
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy
Journal for ImmunoTherapy of Cancer·2023· 65 citedOpen Access
Back in Person: Frontiers in Medicinal Chemistry 2023
ChemMedChem·2023· 1 citedOpen Access
Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Figures from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Tables from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Data from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Data from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Methods from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Figures from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Supplementary Methods from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2023Open Access
Frontiers in Medicinal Chemistry 2022 Goes Virtual
ChemMedChem·2022
Nickel‐Catalyzed <i>N</i>‐Arylation of <i>NH</i>‐Sulfoximines with Aryl Halides via Paired Electrolysis
Angewandte Chemie International Edition·2021· 96 cited
Nickel‐Catalyzed <i>N</i>‐Arylation of <i>NH</i>‐Sulfoximines with Aryl Halides via Paired Electrolysis
Angewandte Chemie·2021· 19 cited
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
Cellular Oncology·2021· 40 cited
The Potent and Selective AMPK Inhibitor BAY-3827 Shows Strong Efficacy in Androgen-Dependent Prostate Cancer Models
2020· 1 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Dominik Mumberg(17), Franz von Nussbaum(16), Benjamin Bader(15), Antje M. Wengner(14), Philip Lienau(14), Gerhard Siemeister(13), Jonathan Clayden(13), Ulf Bömer(12), Christoph A. Schatz(11), Michael Brands(11), Alberto Minassi(11), Lars Wortmann(10), Bernard Haendler(10), Karl Ziegelbauer(10), Morgan Donnard(10), Ulrich Lücking(9), Dieter Moosmayer(9), Uwe Eberspächer(9), Simon J. Baumgart(9), Sven Golfier(8)